1.296 articles found

Microglial inhibition alleviates alpha-synuclein propagation and neurodegeneration in Parkinson's disease mouse model.

Thi Lai T, Kim YE, Nguyen LTN, Thi Nguyen T, Kwak IH, Richter F, Kim YJ, Ma HI.

NPJ Parkinsons Dis · 2024-02-02

DOI: 10.1038/s41531-024-00640-2PMID: 38302446

Extracellular vesicles contain filamentous alpha-synuclein and facilitate the propagation of Parkinson's pathology.

Ishiguro Y, Tsunemi T, Shimada T, Yoroisaka A, Ueno SI, Takeshige-Amano H, Hatano T, Inoue Y, Saiki S, Hattori N.

Biochem Biophys Res Commun · 2024-02-02

DOI: 10.1016/j.bbrc.2024.149620PMID: 38359614

Alpha-synuclein pathology is associated with astrocyte senescence in a midbrain organoid model of familial Parkinson's disease.

Muwanigwa MN, Modamio-Chamarro J, Antony PMA, Gomez-Giro G, Krüger R, Bolognin S, Schwamborn JC.

Mol Cell Neurosci · 2024-02-01

DOI: 10.1016/j.mcn.2024.103919PMID: 38307302

Ribose-cysteine and levodopa abrogate Parkinsonism via the regulation of neurochemical and redox activities in alpha-synuclein transgenic <i>Drosophila melanogaster</i> models.

Idowu OK, Oremosu AA, Dosumu OO, Mohammed AA.

Fly (Austin) · 2024-01-29

DOI: 10.1080/19336934.2024.2306687PMID: 38286464

In silico analysis of alpha-synuclein protein variants and posttranslational modifications related to Parkinson's disease.

da Silva ANR, Pereira GRC, Bonet LFS, Outeiro TF, De Mesquita JF.

J Cell Biochem · 2024-01-18

DOI: 10.1002/jcb.30523PMID: 38239037

Novel Pyrrolo-pyrazol-one Ligands of Alpha-Synuclein for Diagnosis of Parkinson's Disease.

Rosse G.

ACS Med Chem Lett · 2024-01-12

DOI: 10.1021/acsmedchemlett.3c00564PMID: 38352848

Distinct tau and alpha-synuclein molecular signatures in Alzheimer's disease with and without Lewy bodies and Parkinson's disease with dementia.

van der Gaag BL, Deshayes NAC, Breve JJP, Bol JGJM, Jonker AJ, Hoozemans JJM, Courade JP, van de Berg WDJ.

Acta Neuropathol · 2024-01-10

DOI: 10.1007/s00401-023-02657-yPMID: 38198008

Levodopa Rescues Retinal Function in the Transgenic A53T Alpha-Synuclein Model of Parkinson's Disease.

Tran KKN, Wong VHY, Vessey KA, Finkelstein DI, Bui BV, Nguyen CTO.

Biomedicines · 2024-01-08

DOI: 10.3390/biomedicines12010130PMID: 38255235

Cell-to-cell transmitted alpha-synuclein recapitulates experimental Parkinson's disease.

Prymaczok NC, De Francesco PN, Mazzetti S, Humbert-Claude M, Tenenbaum L, Cappelletti G, Masliah E, Perello M, Riek R, Gerez JA.

NPJ Parkinsons Dis · 2024-01-06

DOI: 10.1038/s41531-023-00618-6PMID: 38184623

Regional differences in synaptic degeneration are linked to alpha-synuclein burden and axonal damage in Parkinson's disease and dementia with Lewy bodies.

Frigerio I, Bouwman MMA, Noordermeer RTGMM, Podobnik E, Popovic M, Timmermans E, Rozemuller AJM, van de Berg WDJ, Jonkman LE.

Acta Neuropathol Commun · 2024-01-03

DOI: 10.1186/s40478-023-01711-wPMID: 38173031

Alpha-synuclein in peripheral body fluid as a biomarker for Parkinson's disease.

Shu H, Zhang P, Gu L.

Acta Neurol Belg · 2024-01-03

DOI: 10.1007/s13760-023-02452-2PMID: 38170418

Cerium oxide nanoparticles modulating the Parkinson's disease conditions: From the alpha synuclein structural point of view and antioxidant properties of cerium oxide nanoparticles

Yao X, Guan Y, Wang J, Wang D.

Heliyon · 2024-01-01